Orexigen Therapeutics, Inc.
OREX
OREX was delisted on the 3rd of April, 2018.
41 hedge funds and large institutions have $8.79M invested in Orexigen Therapeutics, Inc. in 2017 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 10 increasing their positions, 11 reducing their positions, and 9 closing their positions.
11% more call options, than puts
Call options by funds: $394K | Put options by funds: $355K
0% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 9
9% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 11
2% less funds holding
Funds holding: 42 → 41 (-1)
27% less capital invested
Capital invested by funds: $12.1M → $8.79M (-$3.32M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GL
GLG LLC
New York
|
+$2.48M |
| 2 |
Daiwa Securities Group
Tokyo,
Japan
|
+$529K |
| 3 |
TI
Telemetry Investments
New York
|
+$105K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$103K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$68.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCMI
Foresite Capital Management II
Larkspur,
California
|
-$1.11M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$204K |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$202K |
| 4 |
HCM
Highbridge Capital Management
New York
|
-$128K |
| 5 |
OWIM
Old West Investment Management
Los Angeles,
California
|
-$127K |
OREX Hedge Fund Activity: Q4 2017 in Review
41 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Orexigen Therapeutics, Inc. (OREX) for Q4 2017, worth a combined $8.79M — down 27% from $12.1M a quarter earlier.
Fund positioning in OREX was balanced in Q4 2017: 9 funds opened new positions, 9 closed out, 10 added to existing stakes and 11 trimmed.
The largest buyer was GLG LLC, opening a new position worth an estimated $2.48M. The largest seller was Foresite Capital Management II, exiting entirely with an estimated $1.11M sold.
- 41 institutional investors held Orexigen Therapeutics, Inc. (OREX) as of Q4 2017, down from 42 in Q3 2017.
- Funds reported $8.79M of Orexigen Therapeutics, Inc. stock for Q4 2017, down 27% quarter-over-quarter.
- 9 funds opened new Orexigen Therapeutics, Inc. positions in Q4 2017 and 9 closed out, a net change of 0 holders.
- The largest Orexigen Therapeutics, Inc. buyer in Q4 2017 was GLG LLC, an estimated $2.48M added.
- The largest Orexigen Therapeutics, Inc. seller in Q4 2017 was Foresite Capital Management II, an estimated $1.11M sold.
Based on aggregated 13F filings for Q4 2017.